Patents by Inventor Peter W. Mason
Peter W. Mason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11639370Abstract: The invention relates to platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using such platforms permits the generation of broad and potent immune responses useful for vaccine development.Type: GrantFiled: June 28, 2021Date of Patent: May 2, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael Franti, Anders Lilja, Rebecca Loomis, Peter W. Mason
-
Publication number: 20220213149Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.Type: ApplicationFiled: March 16, 2022Publication date: July 7, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael FRANTI, Anders LILJA, Rebecca LOOMIS, Peter W. MASON
-
Publication number: 20220119455Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.Type: ApplicationFiled: June 28, 2021Publication date: April 21, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael FRANTI, Anders LILJA, Rebecca LOOMIS, Peter W. MASON
-
Patent number: 11078237Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.Type: GrantFiled: August 28, 2018Date of Patent: August 3, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael Franti, Anders Lilja, Rebecca Loomis, Peter W. Mason
-
Patent number: 10973899Abstract: The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).Type: GrantFiled: February 25, 2016Date of Patent: April 13, 2021Assignee: Novartis AGInventors: Caitlin Jeanette Hagen, Dong Yu, Peter W. Mason, Peter Shahinian
-
Publication number: 20180036398Abstract: The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).Type: ApplicationFiled: February 25, 2016Publication date: February 8, 2018Inventors: Caitlin Jeanette HAGEN, Dong YU, Peter W. MASON, Peter SHAHINIAN
-
Patent number: 9499588Abstract: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.Type: GrantFiled: July 22, 2011Date of Patent: November 22, 2016Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Peter W. Mason, Tomohiro Ishikawa
-
Patent number: 9273288Abstract: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.Type: GrantFiled: July 28, 2012Date of Patent: March 1, 2016Assignee: The Board of Regents of The University of Texas SystemInventors: Peter W. Mason, Elena Frolova, Ilya Frolov
-
Patent number: 8889623Abstract: Provided herein are immunostimulatory nanolipoprotein particles and related compositions methods and systems.Type: GrantFiled: October 22, 2009Date of Patent: November 18, 2014Assignees: Lawrence Livermore National Security, LLC, The Board of Regents of the University of Texas SystemInventors: Paul D. Hoeprich, Nicholas O. Fischer, Craig Blanchette, Peter W. Mason
-
Patent number: 8883729Abstract: Functionalized nanolipoprotein particle presenting an anchor substrate compound for binding with a corresponding anchor compound presented on a target molecule, and related compositions methods and systems.Type: GrantFiled: May 20, 2009Date of Patent: November 11, 2014Assignees: Lawrence Livermore National Security, LLC, The Board of Regents of the University of Texas SystemInventors: Paul D. Hoeprich, Nicholas O. Fischer, Peter W. Mason, Craig D. Blanchette
-
Publication number: 20130023031Abstract: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.Type: ApplicationFiled: July 28, 2012Publication date: January 24, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Peter W. Mason, Elena Frolova, Ilya Frolov
-
Patent number: 8252574Abstract: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.Type: GrantFiled: February 27, 2007Date of Patent: August 28, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Peter W. Mason, Elena Frolova, Ilya Frolov
-
Publication number: 20110311579Abstract: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.Type: ApplicationFiled: July 22, 2011Publication date: December 22, 2011Inventors: Peter W. Mason, Tomohiro Ishikawa
-
Publication number: 20090311276Abstract: Functionalized nanolipoprotein particle presenting an anchor substrate compound for binding with a corresponding anchor compound presented on a target molecule, and related compositions methods and systems.Type: ApplicationFiled: May 20, 2009Publication date: December 17, 2009Inventors: Paul D. Hoeprich, Nicholas O. Fischer, Peter W. Mason, Craig D. Blanchette
-
Publication number: 20090155301Abstract: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.Type: ApplicationFiled: February 27, 2007Publication date: June 18, 2009Inventors: Peter W. Mason, Elena Frolova, Ilya Frolov
-
Patent number: 5866416Abstract: A method of making a genetically-engineered cell line which is susceptible to infection by foot-and-mouth disease virus and allows the virus to replicate is disclosed. The method involves fusing the DNA encoding ICAM-1 with the DNA encoding an antibody specific for foot-and-mouth disease virus and expressing the resulting chimeric cell surface receptor protein. The chimeric cell surface receptor protein allows foot-and-mouth disease virus to bind, leading to subsequent infection and replication of foot-and-mouth disease virus. A genetically-engineered cell which expresses the chimeric cell surface receptor protein is also claimed.Type: GrantFiled: June 24, 1996Date of Patent: February 2, 1999Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Peter W. Mason, Barry Baxt, Elizabeth Reider, Analia Berinstein, Angray S. Kang
-
Patent number: 5824316Abstract: A foot-and-mouth disease virus has been genetically engineered by deleting the nucleic acid sequence encoding the leader (L) proteinase from an infectious cDNA copy of the viral genome and producing an L proteinase-deleted virus. The L proteinase-deleted viruses are able to assemble and grow in cells in culture, but, since they lack L proteinase, they are less toxic to infected cells within the animal, producing an attenuated infection. The recombinant virus can be formulated into an effective vaccine for the prevention of foot-and-mouth disease.Type: GrantFiled: May 24, 1996Date of Patent: October 20, 1998Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Marvin J. Grubman, Peter W. Mason, Maria Elisa Piccone, Elizabeth Rieder
-
Patent number: 5612040Abstract: A safe, effective vaccine for the protection of susceptible animals against foot-and-mouth disease has been produced. The vaccine comprises a mutant virus from which the amino acid sequence Gly-Val-Arg-Gly-Asp-Phe (SEQ ID NO: 8) from the G-H loop of VP1 has been deleted and replaced with the amino acid sequence Asn-Pro. The mutant virus retains its antigenicity but is not infectious.Type: GrantFiled: April 7, 1995Date of Patent: March 18, 1997Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Peter W. Mason, Barry Baxt, Elizabeth Reider, Analia Berinstein, Angray S. Kang